Pembrolizumab plus Chemo Granted Breakthrough Therapy Designation by the FDA
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study Results from the pivotal...
Read MoreOct 20, 2019
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study Results from the pivotal...
Read MoreOct 9, 2019
Progression-free survival no different at five years when radiotherapy is used only if the cancer returns
Read MoreOct 9, 2019
Progression-free survival no different at five years when radiotherapy is used only if the cancer returns
Read MoreOct 8, 2019
Veliparib added to chemotherapy, continued as maintenance tx prolongs progression-free survival
Read MoreOct 4, 2019
Overall survival longer for encorafenib, cetuximab, and binimetinib combo versus standard therapy
Read MoreOct 4, 2019
Benefit seen for addition of CDK4/6 inhibitor after progression of disease on endocrine therapy
Read MoreOct 4, 2019
Benefit seen for addition of CDK4/6 inhibitor after progression of disease on endocrine therapy
Read MoreOct 1, 2019
By Ludwig Burger BARCELONA (Reuters) – GlaxoSmithKline and AstraZeneca both reported trial...
Read MoreSep 30, 2019
Overall survival at five years longer with nivolumab + ipilimumab, nivolumab alone versus ipilimumab
Read MoreSep 28, 2019
By Ludwig Burger BARCELONA (Reuters) – GlaxoSmithKline and AstraZeneca both reported trial...
Read MoreSep 28, 2019
By Deena Beasley (Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small,...
Read MoreSep 26, 2019
By Ludwig Burger (Reuters) – GlaxoSmithKline and AstraZeneca will each present trial data on...
Read More